Quality Control
Functionality tested in Real-time PCR for specificity, sensitivity and reproducibility for each primer sets using hematopoietic cell lines.
PML-RARA Service
NanoCinna Pharmacogenomics Center
PML-RARA
Acute promyelocytic leukemia (APL) is a subtype of Acute myelocytic leukemia (AML) in which there is an overabundance of immature blood cells called “promyelocytes” and deficiency in mature white blood cells. 90% of APL patients consist of PML-RARA and RARA-PML type accounts for ~10% of all cases. The disease is characterized by severe bleeding and defective coagulation (blood clotting). APL is associated with an exchange of DNA from chromosome 15 and chromosome 17, creating a fusion gene PML-RARA that is a transcriptional repressor. RARA breakpoints always occur in intron 2. Depending on the location of breakpoints within the PML site, intron 6, exon 6 and intron 3, the respective PML-RARa transcript subtypes referred to as long (L or bcr1), variant (V or bcr2) and short (S or bcr3), may be formed. Here we used a technique based on PCR to develop a diagnostic test for APL based on detection of all types PML-RARA fusion transcripts Vs ABL control gene.
Application
Diagnosis of acute promyelocytic leukaemia
Detection of 3 types PML-RARA fusion
transcripts (PML-BCR1, PML-BCR2, PML-BCR3)
Sampling Condition
Bone marrow or blood sample needed,
for more information please contact us.
Catalog Number
#S1371 PML-RARA quantitative assay
#S1384 PML-RARA qualitative assay
#S1371 description
APL specific PCR based on the detection of PML-RARA fusion transcripts by 3 forward primers and 1 reverse primer
Characterization of all types (3 types) of PML-RARA transcripts with PCR in a qualitative method.
